EEA/Norwegian Financial Mechanisms and Ministry of education, Youth and Sports of Czech republic
Public support
Provider
Ministry of Education, Youth and Sports
Programme
EEA/Norwegian Financial Mechanism
Call for proposals
—
Main participants
—
Contest type
RP - Co-financing of EC programme
Contract ID
3098/2010-32
Alternative language
Project name in Czech
EEA/Norwegian Financial Mechanisms and Ministry of education, Youth and Sports of Czech republic
Annotation in Czech
The overall objective of this project is to develop new tools that would enable us to find new prognostic markers for childhood leukemia. This effort is in line with a long term goal to reveal new markers relevant for prediction of treatment failure in childhood leukemia. If such markers are found and verified on large cohort, the chemotherapeutic protocols can be adjusted for each patient to correspond with patient's risk of relapse (treatment failure) and in the same time patients can be saved from unnecessary therapy (and its adverse effects) if their risk of relapse is low. Treatment of childhood leukemia is currently achieved by using "protocol treatment" that usually lasts at least 1.5 years and has elaborate sequence of therapeutical modalitiesthat are combined in well controlled international studies. The Czech Republic is a member of the BFM-group (whose members also include Germany-Austria-Italy). This group develops leukemia treatment protocols that are the most successful in current pediatric hematology. Furthermore, several compounds were implemented in the recent years that act as "targeted therapeutics" and target specifically the leukemia associated molecular abnormalities. The best example is imatinib mesylate (glivec) used for leukemias bearing the BCR/ABL translocation and many others small inhibitors. Our current task is to find appropriate role of these new compound in the treatment protocols and to find correlates of good response to these compounds. Large scale protein analysis, such as the antibody array technology is instrumental in finding the profile of good response of the leukemia cells.
Scientific branches
R&D category
ZV - Basic research
CEP classification - main branch
FD - Oncology and haematology
CEP - secondary branch
FG - Paediatrics
CEP - another secondary branch
EC - Immunology
OECD FORD - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)
30102 - Immunology<br>30204 - Oncology<br>30205 - Hematology<br>30209 - Paediatrics
Completed project evaluation
Provider evaluation
U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)
Project results evaluation
Following the condition that the candidate of financial contribution was evaluated and afterwards selected by international provider in accordance with the rules of the program the Ministry of Education, Youth ans Sports does not realize the evaluation of project results. The project is evaluated only after its approval by an international provider
Solution timeline
Realization period - beginning
May 1, 2009
Realization period - end
Oct 31, 2010
Project status
U - Finished project
Latest support payment
May 11, 2010
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP11-MSM-7F-U/01:1
Data delivery date
Jun 30, 2011
Finance
Total approved costs
406 thou. CZK
Public financial support
406 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
0 thou. CZK